Investors Encouraged to Lead Class Action Against Soleno Therapeutics for Securities Fraud

The Schall Law Firm, a prominent national litigation firm that advocates for shareholder rights, has outlined an opportunity for investors affected by Soleno Therapeutics, Inc. (NASDAQ: SLNO) to partake in a class action lawsuit. This legal action stems from purported violations of the Securities Exchange Act of 1934, specifically concerning misleading statements made by the company regarding its drug, diazoxide choline extended-release tablets (DCCR).

Context of the Class Action

The lawsuit is particularly relevant for individuals who purchased Soleno's securities during the class period, which runs from March 26, 2025, to November 4, 2025. Evidence presented in the complaint suggests that Soleno provided inadequate disclosures related to the safety profile and commercial viability of DCCR. These disclosures were claimed to have significantly downplayed serious safety risks revealed during a Phase 3 clinical trial.

It is alleged that Soleno's public statements misrepresented the potential risks associated with DCCR, leading to investor losses once the true nature of the safety concerns became evident. The impact of these revelations resulted in a decline in stock price, affecting those who held securities during the specified timeframe.

Importance of Taking Action

Investors who believe they suffered financial losses as a result of these misstatements are urged to take action before May 5, 2026. The Schall Law Firm highlights that joining this class action not only serves as a way to seek recovery for losses but also provides a platform for voicing concerns over corporate accountability in the biotech sector.

When prospective class members take the step to participate, it enables them to engage with legal representatives who are well-versed in securities litigation. Brian Schall, of the Schall Law Firm, has encouraged affected shareholders to reach out and discuss their rights at no cost. Notably, until the class action is officially certified, potential class members are considered unrepresented legally.

Understanding the Allegations

Investors should note that the allegations against Soleno are rooted in assertions that the company's management misled the market about critical safety issues surrounding their drug. This misconduct, as outlined in the complaint, suggests a pattern of opaque communication with investors that ultimately led to significant reputational harm and financial losses.

The core argument revolves around the assertion that relevant safety concerns surrounding DCCR were not sufficiently disclosed, creating a façade of assurance that ultimately crumbled when the facts emerged. The Schall Law Firm contends that many of the disclosures made by Soleno were materially misleading both at the time they were published and throughout the class period.

Join the Movement

For those concerned about their investments in Soleno Therapeutics, this lawsuit presents an opportunity to seek justice. The Schall Law Firm is dedicated to not only representing affected investors but also to fostering an environment where companies are held accountable for misleading their shareholders.

In conclusion, potential claimants are encouraged to reach out to the Schall Law Firm for a free consultation regarding participation in this class action. By standing together, investors can push back against corporate malfeasance and strive to recover their rightful losses. For further details, individuals may contact the law firm or visit their website.

Investors who have sustained losses during this timeframe have until the outlined deadline to act, making it critical to assess the situation promptly and understand their legal options moving forward.